Skip to main content
Equibles
PCYN logo

PCYN · Procyon Corp

Track PCYN — free

Use PCYN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PCYN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.19 At close · Oct 19
Rebalance outlook locked
Customer concentration — top customer 10% of revenue

One customer — 10% of revenue (fiscal 2024)

“In fiscal 2024 one customer accounted for approximately 10% of AMERX’s sales.”

One customer — 10% of revenue (fiscal 2023)

“During the year ended June 30, 2023 sales from one customer accounted for approximately 10% of AMERX’s sales.”
View the 10-K filed Oct 25, 2024
Market Cap
$1.50M
Shares
8.12M
Volume · Oct 19 100 Avg daily vol (12 sessions) 5322

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.19 Open$0.19 Day$0.19–0.19 52W close$0.12–0.28 Avg vol 30d7K Short int160 · 0.0% float · 1.0d Short vol100% DataJan 2020–Oct 2026 Filing10-K · Oct 25

Up next

Latest filing: 10-K
filed Oct 25, 2024

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$4.98M
Trailing 12 months
Net income (TTM)
−$341,140
Trailing 12 months
Revenue growth YoY
+17.5%
Year over year
Operating margin
-4.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-8.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.3%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 19.5 · elevated Equity put/call 0.67
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −33%
below
Price vs 50-day avg −9%
below
RSI (14) 44
neutral
MACD trend Negative
52-week position 40%
mid-range
Momentum
relative strength
Weak
1-month return −34%
trailing
6-month return −16%
trailing
YTD return +53%
this year
Relative strength −24%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Fundamentals
Weak
Revenue growth +6%
Y/Y
Gross margin 78%
expanding
EPS growth −300%
Y/Y
Free cash flow $-125.2K
Quant / Vol
risk profile
Very High
Volatility 14546%
annualized · 1-yr
Max drawdown −100%
past year
ATR 15.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−33% Bearish
Price vs 50-day avg
−9% Bearish
RSI (14)
44 Neutral
MACD trend
Negative Bearish
52-week position
40% Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0 Now $0 · 40% Range high $0
vs 200-day avg -33% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PCYN
Procyon Corp
this stock
$1.50M — +6.4% — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $64.66B +29.8% — — 0.1%
GALDY
Galderma Group AG
 $53.98B +11.7% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $45.92B +26.3% +4.3% 64.6 2.6%
HLN
Haleon plc
 $45.16B +1.6% — — 0.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest
Shares short
160
Days to cover
1.0d
Change
0 sh
View
Short Volume
Short vol %
100%
As of
Sep 28, 2026
Short Total
View
Fails to Deliver
FTD shares
1.5K
Value
$336
As of
Dec 26, 2024
View
Off-Exchange
Off-exchange %
100.0%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$5.0M
Net income (FY)
$-341.1K
EPS diluted
$-0.04
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 8, 2024
This year
0
View
Proposed Sales
Value
$7.3K
Shares
40.0K
Filed
Jun 26, 2024
View

Performance

5D 20D 120D MTD YTD
PCYN -26.0% -33.9% -16.1% -31.5% +52.9%
SPY -1.5% -0.9% +7.7% +0.5% +12.4%
vs SPY -24.5% -33.0% -23.8% -32.0% +40.5%
Key facts CIK 812306 Visit website